Cargando…
The fastest national COVID vaccination in Europe - Malta's strategies
BACKGROUND: COVID-19 vaccines reduce morbidity and mortality, but mass vaccination faces multiple challenges leading to different vaccination rates in different countries. Malta, a small European country, has achieved a very rapid vaccination rollout. This paper presents a narrative review of Malta&...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687735/ https://www.ncbi.nlm.nih.gov/pubmed/34977913 http://dx.doi.org/10.1016/j.hsr.2021.100001 |
_version_ | 1784618234231652352 |
---|---|
author | Cuschieri, Sarah Agius, Steve Souness, Jorgen Brincat, Andre Grech, Victor |
author_facet | Cuschieri, Sarah Agius, Steve Souness, Jorgen Brincat, Andre Grech, Victor |
author_sort | Cuschieri, Sarah |
collection | PubMed |
description | BACKGROUND: COVID-19 vaccines reduce morbidity and mortality, but mass vaccination faces multiple challenges leading to different vaccination rates in different countries. Malta, a small European country, has achieved a very rapid vaccination rollout. This paper presents a narrative review of Malta's vaccination strategy and its impact on the country's COVID-19 situation. METHODS: Data was obtained through a literature review of Maltese newspapers and from Malta's COVID-19 government dashboard. A comprehensive summary of vaccination operations was provided by Malta's COVID-19 vaccination team. RESULTS: Malta comprised part of the European Commission joint procurement and obtained the maximum vaccines that were eligible from all manufacturers. Four tier priority population groups were set up, with both vaccine doses (where applicable) allocated and stored for each individual. Multiple hubs were set up to simultaneously administer first and eventually second doses accordingly. To date (August 9, 2021) 398,128 of the population are fully vaccinated and 405,073 received the first dose, with both morbidity and mortality declining progressively as vaccination coverage progressed. CONCLUSION: Malta has successfully implemented a COVID-19 strategy that rapidly covered a substantial proportion of the population over a short period of time, with herd immunity reached by end of May 2021. Low population vaccination hesitancy and high vaccine doses availability were two major factors in this success. |
format | Online Article Text |
id | pubmed-8687735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86877352021-12-21 The fastest national COVID vaccination in Europe - Malta's strategies Cuschieri, Sarah Agius, Steve Souness, Jorgen Brincat, Andre Grech, Victor Health Sci Rev (Oxf) Article BACKGROUND: COVID-19 vaccines reduce morbidity and mortality, but mass vaccination faces multiple challenges leading to different vaccination rates in different countries. Malta, a small European country, has achieved a very rapid vaccination rollout. This paper presents a narrative review of Malta's vaccination strategy and its impact on the country's COVID-19 situation. METHODS: Data was obtained through a literature review of Maltese newspapers and from Malta's COVID-19 government dashboard. A comprehensive summary of vaccination operations was provided by Malta's COVID-19 vaccination team. RESULTS: Malta comprised part of the European Commission joint procurement and obtained the maximum vaccines that were eligible from all manufacturers. Four tier priority population groups were set up, with both vaccine doses (where applicable) allocated and stored for each individual. Multiple hubs were set up to simultaneously administer first and eventually second doses accordingly. To date (August 9, 2021) 398,128 of the population are fully vaccinated and 405,073 received the first dose, with both morbidity and mortality declining progressively as vaccination coverage progressed. CONCLUSION: Malta has successfully implemented a COVID-19 strategy that rapidly covered a substantial proportion of the population over a short period of time, with herd immunity reached by end of May 2021. Low population vaccination hesitancy and high vaccine doses availability were two major factors in this success. Published by Elsevier Ltd. 2021 2021-10-04 /pmc/articles/PMC8687735/ /pubmed/34977913 http://dx.doi.org/10.1016/j.hsr.2021.100001 Text en © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Cuschieri, Sarah Agius, Steve Souness, Jorgen Brincat, Andre Grech, Victor The fastest national COVID vaccination in Europe - Malta's strategies |
title | The fastest national COVID vaccination in Europe - Malta's strategies |
title_full | The fastest national COVID vaccination in Europe - Malta's strategies |
title_fullStr | The fastest national COVID vaccination in Europe - Malta's strategies |
title_full_unstemmed | The fastest national COVID vaccination in Europe - Malta's strategies |
title_short | The fastest national COVID vaccination in Europe - Malta's strategies |
title_sort | fastest national covid vaccination in europe - malta's strategies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687735/ https://www.ncbi.nlm.nih.gov/pubmed/34977913 http://dx.doi.org/10.1016/j.hsr.2021.100001 |
work_keys_str_mv | AT cuschierisarah thefastestnationalcovidvaccinationineuropemaltasstrategies AT agiussteve thefastestnationalcovidvaccinationineuropemaltasstrategies AT sounessjorgen thefastestnationalcovidvaccinationineuropemaltasstrategies AT brincatandre thefastestnationalcovidvaccinationineuropemaltasstrategies AT grechvictor thefastestnationalcovidvaccinationineuropemaltasstrategies AT cuschierisarah fastestnationalcovidvaccinationineuropemaltasstrategies AT agiussteve fastestnationalcovidvaccinationineuropemaltasstrategies AT sounessjorgen fastestnationalcovidvaccinationineuropemaltasstrategies AT brincatandre fastestnationalcovidvaccinationineuropemaltasstrategies AT grechvictor fastestnationalcovidvaccinationineuropemaltasstrategies |